Session thématisée Les Innovations diagnostiques en cancérologie

Size: px
Start display at page:

Download "Session thématisée Les Innovations diagnostiques en cancérologie"

Transcription

1 10 èmes Journées Scientifiques du Cancéropôle Nord-Ouest mai 2017, Deauville Session thématisée Les Innovations diagnostiques en cancérologie Les signatures multigéniques pronostiques dans le cancer du sein Martine J. Piccart-Gebhart, MD, PhD Institut Jules Bordet, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair

2 Disclosures No conflict of interest with any of the companies which are marketing gene expression signatures

3 BREAST CANCER TODAY Significant Progress Achieved Incidence Mortality Ferlay J. Globocan 2012

4 BREAST CANCER TODAY 5 year survival rates (SEER)

5 ADJUVANT SYSTEMIC THERAPY FOR BREAST CANCER TODAY The Age of Escalation Targeted therapy Targeted therapy SX Chemo RT Endocrine therapy Cure a substantial proportion of women Treatment duration : anywhere from 1 day to 15 years!

6 ADJUVANT SYSTEMIC THERAPY FOR BREAST CANCER TODAY The Age of Escalation More Patients Treated Longer Drug Exposure More Drugs Therapeutic Escalation

7 TREATMENT ESCALATION Consequences The cost threatens to blow up our health care systems the ones that actually pay for treatments! Many women live longer but bear the consequences of our aggressive treatments and we can never ignore this!

8 BREAST CANCER «Adjuvant» medical therapies Lung Liver Bone Localized disease Curable But risk of : overtreatment undertreatment wrong treatment suboptimal treatment Generalized disease Very difficult to cure

9 ADJUVANT SYSTEMIC THERAPY FOR EARLY BREAST CANCER Benefit / Risk Balance Lessons learned from 3 decades of clinical trials BENEFIT Survival (2 to 12%) POTENTIAL HARM Mood alterations Thrombo-embolic events Arthralgia Osteoporosis LONG-TERM RISKS Secondary cancers Cardiac toxicity Early menopause Cognitive function AND SOCIO-ECONOMIC BURDEN

10 ST. GALLEN DEFINITIONS OF RISK Low G1 T 2 Node HER2 LVI absent Only 20% of patients! R I S K Intermediate High AGE < 35 G2-3 T>2 Node, HER2+ or LVI present Node + (1-3) and HER2 - Node + (1-3) and HER2 + Node + 4 Most difficult group for CT decision! R I S K Other similar guidelines exist : NCCN, ESMO,

11 IMPROVED RISK ASSESSMENT OF EARLY BREAST CANCER THROUGH GENE EXPRESSION PROFILING L. van t Veer R. Bernards 78 untreated N primary tumors 295 partially treated N / N + tumors 44 w/o relapse at 8 y follow-up 34 with a relapse within 5 y microarray Gene-expression profile 5000 genes 231 genes 70 genes Poor prognosis signature van t Veer L., Nature 2002; 415 (31) : Van de Vijver MJ, N Engl J Med 2002; 347 (24):

12 B.C. CLINICAL OUTCOME PREDICTION 70-gene profiler outperforms St Gallen criteria Van de Vijver MJ, N Engl J Med 2002; 347 (24):

13 Validation of the MammaPrint signature : 15 years of intensive collaborative work! Signature ublished External validation of the signature by the TransBIG network Conduct of MINDACT MINDACT Results

14 EORTC-BIG Mindact Trial Design node negative & 1-3 node positive women 70-gene signature (Mammaprint ) risk AND Clinical-Pathological risk Both low risk Discordant cases Both high risk No chemotherapy Randomization Chemotherapy Supported by the EU 6th framework grant (7 million euros) Total cost of trial 45 million euros!

15 Tumor biology MammaPrint Low vs High genomic risk VERSUS Tumor anatomy (+ a few biological features) Adj.! Online Low vs High clinical risk Hypothesis : the Genomic assay will outperform the Clinical criteria by reducing the prescription of adjuvant chemotherapy WITHOUT IMPAIRING OUTCOME More specifically: clinically high risk patients with a low risk gene signature randomized not to receive CTX should have a 5 year DMFS of 92%

16 The MINDACT study: Patient demographics Clinical «low risk» (50%) Clinical «high risk» (50%) N = 6693 Median age = 55y Node - 79% Node + 21% T1 tumours 72% Grade 2 49% HR positive 88% HER2+ 10% N=2745 Discordant N=1806 clinical Low/ genomic Low N=592 N=1550 clinical High/ genomic High clinical Low/ genomic High clinical High/ genomic Low

17 ER positive HER2 negative ER status HER2 status Grade Nodal status Tumor size Clinical Risk in MINDACT well differentiated N 1-3 positive nodes 3cm C-low cm C-high 2 cm C-low cm C-high moderately differentiated N 1-3 positive nodes 2 cm C-low cm C-high Any size C-high poorly differentiated OR undifferentiated N 1-3 positive nodes 1 cm C-low cm C-high Any size C-high C-high risk : expected 10 y OS < 92% with endocrine therapy alone (as per Adjuvant! Online)

18 The MINDACT study at a median follow-up of 5 years N = 6693 women N = 672 relapses 208 deaths N = 362 distant relapses

19 Clinical outcome of the MINDACT population at 5y median follow-up DMFS IN ALL 4 RISK GROUPS

20 Clinical outcome of the MINDACT population at 5y median follow-up DISCORDANT RISK GROUPS: PRIMARY TEST The primary analysis population Discordant risks The primary statistical test (DMFS at 5Y) c-low /g-high c-high/g-low RANDOMIZATION No chemotherapy N = 748 CT No change in risk post enrollement and no CT received N = 644 Null Hypothesis: set at 92% Observed 5Y DMFS = 94.7% 95% CI % excludes 92%!!!

21 MINDACT: whole population vs key subgroup MINDACT Entire population (N=6693) MINDACT High clin risk/low genomic risk (N=1550) T1 72% T1 42% T2 27% T2 54% T3 1% T3 4% N0 79% N0 52% N1-3 21% 1+ node 33% 2+ nodes 10% G1 G2 G3 22% 29% 49% 3+ nodes G1 G2 G3 5% 6% 29% 64% Er PR HER2+ 12% 9,5% Er PR HER2+ 2% 8% Low proportion Less confidence in the results?

22 Can we be sure that modern pathology is not also able to distinguish indolent luminal cancers from aggressive ones?

23 Discordances between central immunohistochemical and molecular breast cancer subtyping in the MINDACT trial luminal tumors (N=4718) Molecular subtyping based on BluePrint and MammaPrint Pathological subtyping Luminal A ER+ and PgR 20% and HER2- and Ki67 < 20% Luminal B ER+ and PgR < 20% and/or Ki67 20% and HER2-

24 Can we be sure that adjuvant CT does not provide a benefit in the discordant groups?

25 Efficacy: CT vs no CT in discordant risk groups Intent-to-treat analysis Distant Metastasis Free Survival c-high/g-low Distant Metastasis Free Survival c-low/g-high Allocated Treatment strategy CT % at 5 Year(s) (95% CI) 95.9 (94.0, 97.2) Hazard Ratio (adjusted Cox model) (95% CI) 0.78 (0.50,1.21) p-value (adjusted logrank) Allocated Treatment strategy CT % at 5 Year(s) (95% CI) 95.8 (92.9, 97.6) Hazard Ratio (adjusted Cox model) (95% CI) 1.17 (0.59,2.28) p-value (adjusted logrank) no CT 94.4 (92.3, 95.9) no CT 95.0 (91.8, 97.0) Allocated to: Allocated to: Small CTX benefit not ruled out but 2% No suggestion of any CT benefit

26 Adjuvant therapy decision-making NEVER FORGET THAT The «low-enough» risk that justifies treatment de-escalation is a patient s decision! «High risk» does not mean that the treatment will work!

27 Practical use of MammaPrint in the clinic Start by evaluating the Clinical Risk * Clinical risk LOW Treatment according to guidelines Clinical risk HIGH Discuss with patient if she would value a < 2% gain in DMFS with adjuvant CTX *Exclude women with T3 or N2 3+? NO Order MammaPrint test In 48% of patients it will come back low risk allowing for adjuvant CTX sparing YES Proceed with CTX

28 Are there ways to forgo GEPs??? Dr M de Block Minister of Health

29 More than 15 years of research and still a lot of controversy regarding who can be spared adjuvant chemotherapy and who does not need extended adjuvant endocrine therapy!!!

30 SYSTEMIC THERAPY FOR EARLY BC Gene Signatures assisting with decision making OnCoG GI oncodna /Myriad Most useful in Node negative disease Ribinikar D - ASCO Educational Book 2016

31 Proliferation genes drive the prognostic power of GEP signatures Original signature Proliferation genes Original signature Non-Proliferation genes Sotiriou C, et al. N Engl J Med. 2009; Wirapati P, et al. Breast Cancer Res. 2008; Sotiriou C, et al. Nat Rev Cancer. 2007

32 LOE 1A (Prospective Validation) MINDACT (MammaPrint) TAILORX (Oncotype Dx) RxPONDER (Oncotype Dx) ASTER70 (Genomic Grade) Reported Partial results reported Expected final results 2017 Expected results 2022 Expected results 2018

33 Adjuvant therapy decision-making NEVER FORGET THAT The «history» of luminal BC extends beyond 5 years, with late relapses seen particularly if large T a/o N+

34 SABCS 2016 New data regarding MammaPrint An ultra low risk cut-off identifies N- postmemopausal women with excellent 20-year outcomes

35 Molecular definition of Indolent 70 gene Prognosis Signature: Ultra-low Threshold 70 significant prognosis genes Ultralow Threshold van t Veer et al., Nature,2002 Threshold derived from TRANSBIG with 25-year follow-up and no metastatic events In women with breast cancer and WITHOUT ANY SYSTEMIC THERAPY This presentation is the intellectual property of the author. Contact them at laura.esserman@ucsf.edufor permission to reprint and/or distribute.

36 Validation in the STO 3 Trial postmenopausal women, <3cm, N0 tumors Stockholm: This presentation is the intellectual property of the author. Contact them at laura.esserman@ucsf.edufor permission to reprint and/or distribute.

37 All Patients by 70 Gene, Ultralow, low ultralow, high This presentation is the intellectual property of the author. Contact them at permission to reprint and/or distribute.

38 Intergroup TAILORx Trial (N=10,253) Trial Assigning IndividuaLized Options for Treatment Node Negative ER+ and/or PgR+ HER2 negative (IHC 0-1+ or FISH [-]) 21-Gene Recurrence Score Assay RS <11 Hormonal Therapy* 16% Results released in 2015 RS Randomize Hormonal Rx* vs Chemotherapy* + Hormonal Rx* 67% RS >25 Chemotherapy* + Hormonal Rx* 17% *Choice of therapy at investigator discretion including option of adjuvant chemotherapy trials

39 TAILORx: RS 0-10 N=1626 / 88 events at median follow-up of 69 months Rate of freedom from recurrence at distant site : 99.3% (95% ci: ) Distant recurrences N=10 Locoregional recurrences N=8 Contralateral BC (invasive) N=15 Other primary cancers N=43 30 deaths (12 w/o cancer) Sparano J.A. et al, N Engl J Med, Nov 19, 2015

40 Stage (N) still matters Prognostic Signatures are not good enough if high tumor burden! Trans ATAC (Oncotype DX) NKI Validation (MammaPrint) LN- LN+ Dowsett et al., J Clin Oncol Van de Vijver et al., NEJM 2002

41 SABCS 2016 (Sestak et al) Head to head comparison of several signatures and their added value beyond a clinical treatment score in Node or Node + patients from ATAC treated with endocrine therapy only Clinical treatment score: N status, T size, grade, age, therapy Signatures: RS (Oncotype-DX), BCI, ROR score (Prosigna)*, EndoPredict Clinical** *incorporates T size ** incorporates T size and nodal status

42 Head to head comparison of multigene prognostic signatures in the ATAC trial N = 818 women (591 N, 227 N + ) 10 year distant recurrence rate 5-10 year distant recurrence rate 29% 10% 6% 14% N N + N N +

43 San Antonio Breast Cancer Symposium December 6-10, 2016 Prognostic value years 0-10 node-negative CTS 31,8 % Improvement IHC4 30,6 IHC ,1 53.8% BCI 43,8 BCI ,5 70.8% RS 22,8 RS ,6 33.3% ROR 50,8 ROR ,7 74.5% EPclin 40,6 EPclin ,2 47.8% Likelihood Ratio χ 2 Likelihood Ratio χ 2 This presentation is the intellectual property of the author/presenter. Contact i.sestak@qmul.ac.uk for permission to reprint and/or distribute.

44 San Antonio Breast Cancer Symposium December 6-10, 2016 Prognostic value years 0-10 node-positive CTS 40,2 % Improvement IHC4 6,3 IHC ,8 11.9% BCI 9,6 BCI ,2 12.9% RS 6,4 RS % ROR 15,5 ROR % EPclin 35,6 EPclin ,5 21.1% Likelihood Ratio χ 2 Likelihood Ratio χ 2 This presentation is the intellectual property of the author/presenter. Contact i.sestak@qmul.ac.uk for permission to reprint and/or distribute.

45 Prognostic (± predictive) value of multigene signatures in years 0-10 Node negative disease: all signatures show added value beyond the Clinical Treatment Score and identify 55 to 70% of patients as having a 10y risk of distant metastases ranging between 3 and 6.6% Node positive disease: the added value of the signatures is inexistent or modest (ROR, EndoPredict Clinical) EndoPredict Clinical identifies 19% of patients with a 10y risk of distant mets below 6%

46 CTS 16,6 San Antonio Breast Cancer Symposium December 6-10, 2016 Prognostic value years 5-10 node-negative % Improvement IHC4 6,6 IHC ,3 20.0% BCI 19,5 BCI ,2 67.5% RS 3,4 RS ,9 11.4% ROR 31,3 ROR , % EPclin 24.0 EPclin ,3 62.0% Likelihood Ratio χ 2 Likelihood Ratio χ 2 This presentation is the intellectual property of the author/presenter. Contact i.sestak@qmul.ac.uk for permission to reprint and/or distribute.

47 CTS 16.0 San Antonio Breast Cancer Symposium December 6-10, 2016 Prognostic value years 5-10 node-positive % Improvement IHC4 1.0 IHC ,2 7.5% BCI 3,1 BCI ,8 11.3% RS 1,1 RS % ROR 7,3 ROR % EPclin 14,9 EPclin ,4 27.5% Likelihood Ratio χ 2 Likelihood Ratio χ 2 This presentation is the intellectual property of the author/presenter. Contact i.sestak@qmul.ac.uk for permission to reprint and/or distribute.

48 Prognostic (± predictive) value of multigene signatures in years 5-10 Node negative disease: added value is seen for BCI, ROR and EndoPredict Clinical. EndoPredict Clinical identifies 73.5% of patients with a risk of distant relapse of 4.3% Node positive disease: a modest added value is seen for signatures that combine genomic with anatomic information. EndoPredict Clinical, for examples, identifies 22% of patients with a risk of distant relapse of 3.3%

49 What about the predictive power of the gene signatures for: - CTX benefit - Endocrine therapy benefit?

50 High proliferative breast cancers may benefit from adjuvant chemotherapy CMF regimen LN- CAF regimen LN+ Paik et al., JCO 2006 Albain et al., Lancet Oncology 2009

51 Breast Cancer Index Algorithmic combination of proliferation related gene signature (Molecular Grade Index) and an estrogen signaling pathway signature (Hox B13/IL17 BR, H/I)

52 Summary of BCI Predictive (H/I) Validation Data H/I shown to be a significant predictor of endocrine benefit in 3 randomized trial cohorts Study Cohort Treatment Predictive analysis Interaction P value Stockholm (n=600) 1 TransATAC (n=665) 2 MA.17 (n=249) 3 Adjuvant tamoxifen vs untreated Adjuvant anastrozole vs tamoxifen Extended letrozole vs placebo H/I High HR: 0.35 ( ); p= H/I Low HR: 0.67 ( ), p= H/I High HR: 0.51 ( ); p=0.04 H/I Low HR: 1.33 ( ), p= H/I High OR: 0.33 ( ); p=0.006 H/I Low OR: 0.58 ( ), p= Results suggest generalizability as an endocrine response biomarker 1. Zhang Y, et al. Clin Cancer Res. 2013;19(15): Sgroi D, et al. Lancet Oncol Oct;14(11): Sgroi et al, J Natl Cancer Inst. 2013;105:

53 Which signature for which patient? Luminal BC patients, aged 40y, No or N1-3+ at diagnosis Low clinical risk as per MINDACT High clinical risk as per MINDACT Patient willing to have CTX for very small benefit Patient unwilling to have CTX for small benefit SIGNATURE SIGNATURE SIGNATURE Prognosis within 5y most relevant (N ) Prognosis within 10y most relevant (N + ) - MammaPrint - Oncotype - EndoPredict, BCI, ROR EndoPredict, BCI, ROR Not accepted by guidelines

54 Which signature for which patient? Luminal BC patients, aged 40y, No or N1-3+ after 5y of endocrine therapy (and no CTX!) Node BCI, ROR, EndoPredict Clinical all useful EndoPredict Clinical identifies 73% of patients with a distant relapse risk of 4.3% Node + Only ROR and EndoPredict Clinical add value but in a modest way EndoPredict Clinical identifies 22% of patients with a distant relapse risk of 3.3% Not accepted currently by guidelines

55 TAILORING OF SYSTEMIC THERAPY FOR EARLY BC Multi Gene Signatures Time to move to the next chapter Bardelli A et al Cancer Cell /j.ccell

56 BREAST Data Center Team BIG HeadquartersTeam Institut Jules Bordet Team BIG Executive Board

57 Backups

58 EBCTCG, submitted (2017)

59 EBCTCG, submitted (2017)

60 EBCTCG, submitted (2017)

61 EBCTCG, submitted (2017)

62 EBCTCG, submitted (2017)

63 Reclassification with molecular subtyping Molecular Subtyping classified 54% as Luminal A among the Luminal B by Pathological Subtyping (PS). MS classified 38% as Luminal (A and B) and 5% as Basaltype among the HER2+ by PS. MS classified 5% as Luminal (A and B) among the TN cases by PS. This presentation is the intellectual property of the author/presenter. Contact them at fatimacardoso@fundacaochampalimaud.pt for permission to reprint and/or distribute.

64 Adjuvant! Online for breast cancer (Updated version) used for a standardized approach to Clinical Risk P. Ravdin

65 Interpretation of the ATAC multigene signature comparison study All patients received endocrine treatment! Node negative disease: all signatures show added value and perform well in years 0-10 and in years 5-10 Node positive disease: the performance of the signatures is more modest and only the ones that integrate tumor burden are useful; more research here is needed

Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI

Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo BREAST CANCER Brain Adjuvant Medical Therapies

More information

OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER

OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER Aleix Prat, MD PhD Medical Oncology Department Hospital Clínic of Barcelona University of Barcelona esmo.org Disclosures Advisory role for

More information

Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA

Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements

More information

Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?

Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London

More information

Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President

Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President Symposium «Evaluation of the Belgian Cancer Plan» Brussels, November 26th, 2012 Personalized oncology in Europe: only a dream if national health systems do not get involved in diagnostics and pivotal cancer

More information

Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011

Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of

More information

Adjuvant endocrine therapy (essentials in ER positive early breast cancer)

Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine

More information

Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer

Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin

More information

8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview

8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay

More information

CARCINOMA DELLA MAMMELLA La scelta del trattamento adiuvante: utilità clinica dei tests genomici

CARCINOMA DELLA MAMMELLA La scelta del trattamento adiuvante: utilità clinica dei tests genomici CARCINOMA DELLA MAMMELLA La scelta del trattamento adiuvante: utilità clinica dei tests genomici Dott.ssa Gaia Griguolo DiSCOG-Università di Padova IOV Istituto Oncologico Veneto I.R.C.C.S. Tutor: Prof.

More information

Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint

Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical

More information

The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer

The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate

More information

She counts on your breast cancer expertise at the most vulnerable time of her life.

She counts on your breast cancer expertise at the most vulnerable time of her life. HOME She counts on your breast cancer expertise at the most vulnerable time of her life. Empowering the right treatment choice for better patient outcomes. The comprehensive genomic assay experts trust.

More information

Rationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York

Rationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Rationale For & Design of TAILORx Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Declining Breast Cancer Mortality & Event Rates in Adjuvant

More information

30 years of progress in cancer research

30 years of progress in cancer research Breast Cancer Molecular Knowledge Integrated in Clinical Practice Personalized Medicine Laura J. Esserman UCSF Comprehensive Cancer Center Retreat Breast Cancer Management Advances 80-90s 1) Screening

More information

Evolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology

Evolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic

More information

Profili di espressione genica

Profili di espressione genica Profili di espressione genica Giampaolo Bianchini MD Ospedale San Raffaele, Milan - Italy Gene expression profiles Transcriptomics Gene DNA mrna mirnas Protein metilation Metabolite Genomics Transcriptomics

More information

Breast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)

Breast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive

More information

Extended Hormonal Therapy

Extended Hormonal Therapy Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early

More information

Considerations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology

Considerations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment

More information

Kathy Albain, MD. Chemotherapy in Luminal Breast Cancer: Who Benefits? Loyola University Chicago Stritch School of Medicine

Kathy Albain, MD. Chemotherapy in Luminal Breast Cancer: Who Benefits? Loyola University Chicago Stritch School of Medicine Chemotherapy in Luminal Breast Cancer: Who Benefits? Kathy Albain, MD Loyola University Chicago Stritch School of Medicine, Director, Breast Clinical Research Program, Cardinal Bernardin Cancer Center,

More information

Oncotype DX testing in node-positive disease

Oncotype DX testing in node-positive disease Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype

More information

The Oncotype DX Assay A Genomic Approach to Breast Cancer

The Oncotype DX Assay A Genomic Approach to Breast Cancer The Oncotype DX Assay A Genomic Approach to Breast Cancer Pathology: 20 th and 21 st Century Size Age Phenotype Nodal status Protein/Gene Genomic Profiling Prognostic & Predictive Markers Used in Breast

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Assays of Genetic Expression in Tumor Tissue as a Technique Page 1 of 67 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Assays of Genetic Expression in Tumor Tissue

More information

Breast Cancer Assays of Genetic Expression in Tumor Tissue

Breast Cancer Assays of Genetic Expression in Tumor Tissue Breast Cancer Assays of Genetic Expression in Tumor Tissue Policy Number: Original Effective Date: MM.12.009 12/02/2008 Line(s) of Business: Current Effective Date Section: 05/25/2018 Other Miscellaneous

More information

MammaPrint, the story of the 70-gene profile

MammaPrint, the story of the 70-gene profile MammaPrint, the story of the 70-gene profile René Bernards Professor of Molecular Carcinogenesis The Netherlands Cancer Institute Amsterdam Chief Scientific Officer Agendia Amsterdam The breast cancer

More information

ersonalized adjuvant therapy based on clinica trials in breast cancer: dream or reality?

ersonalized adjuvant therapy based on clinica trials in breast cancer: dream or reality? Global Breast Cancer Conference Jeju Island, Korea 20-22 April 2017 ersonalized adjuvant therapy based on clinica trials in breast cancer: dream or reality? Martine J. Piccart Gebhart, MD, PhD Institut

More information

ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA

ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)

More information

Adjuvan Chemotherapy in Breast Cancer

Adjuvan Chemotherapy in Breast Cancer Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality

More information

Sesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015

Sesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015 Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant

More information

Genomic platforms in breast cancer

Genomic platforms in breast cancer Genomic platforms in breast cancer Prof. Miguel Martín Instituto de Investigación Sanitaria Hospital Gregorio Marañón Universidad Complutense Madrid mmartin@geicam.org Disclosure Dr. Martin has received

More information

Learning Objectives. Financial Disclosure. Breast Cancer Quality Improvement Project with Oncotype DX. Nothing to disclose

Learning Objectives. Financial Disclosure. Breast Cancer Quality Improvement Project with Oncotype DX. Nothing to disclose Breast Cancer Quality Improvement Project with Oncotype DX Denise Johnson Miller, MD, FACS Medical Director Breast Surgery Hackensack Meridian Health Legacy Meridian (Jersey Shore University Medical Center,

More information

The Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer

The Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer The Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer Erin Roesch, MD, and Claudine Isaacs, MD Abstract Endocrine therapy in the adjuvant setting

More information

Clinical utility of multigene profiling assays in early-stage breast cancer

Clinical utility of multigene profiling assays in early-stage breast cancer PRACTICE GUIDELINE CLINICAL UTILITY OF MULTIGENE PROFILING ASSAYS, Chang et al. Clinical utility of multigene profiling assays in early-stage breast cancer M.C. Chang md phd,* L.H. Souter phd, S. Kamel-Reid

More information

Adjuvant Endocrine Therapy: How Long is Long Enough?

Adjuvant Endocrine Therapy: How Long is Long Enough? Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to

More information

MP Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients With Breast Cancer. Related Policies None

MP Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients With Breast Cancer. Related Policies None Medical Policy Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients With Breast BCBSA Ref. Policy: 2.04.36 Last Review: 11/15/2018 Effective Date: 02/15/2019 Section:

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Assays of Genetic Expression in Tumor Tissue as a Technique Page 1 of 55 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Assays of Genetic Expression in Tumor Tissue

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Assays of Genetic Expression in Tumor Tissue as a Technique Page 1 of 47 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Assays of Genetic Expression in Tumor Tissue

More information

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT

More information

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Policy Number: 2.04.36 Last Review: 9/2018 Origination: 1/2006 Next Review: 9/2019 Policy

More information

38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %

38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI % 38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Assays of Genetic Expression in Tumor Tissue as a Technique Page 1 of 54 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Assays of Genetic Expression in Tumor Tissue

More information

Is Gene Expression Profiling the Best Method for Selecting Systemic Therapy in EBC? Norman Wolmark Miami March 8, 2013

Is Gene Expression Profiling the Best Method for Selecting Systemic Therapy in EBC? Norman Wolmark Miami March 8, 2013 Is Gene Expression Profiling the Best Method for Selecting Systemic Therapy in EBC? Norman Wolmark Miami March 8, 2013 Changing Phases claudin low Lum A Lum B Basal Her2 NIH Consensus Development Panel,

More information

The Current Status and the Future Prospects of Multigene testing in Europe

The Current Status and the Future Prospects of Multigene testing in Europe The Current Status and the Future Prospects of Multigene testing in Europe Emiel J. Rutgers The Netherlands Cancer Institute Antoni Van Leeuwenhoek Hospital Amsterdam St. Gallen Recommendations 2009 =

More information

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Policy Number: 2.04.36 Last Review: 1/2019 Origination: 1/2006 Next Review: 9/2019 Policy

More information

Advances in the Diagnosis and Treatment of Breast Cancer. Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD

Advances in the Diagnosis and Treatment of Breast Cancer. Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD Advances in the Diagnosis and Treatment of Breast Cancer Carol Tweed, M.D. Anne Arundel Medical Center DeCesaris Cancer Institute Annapolis, MD Disclosures Genomic Health: Speaker and Consultant AstraZeneca:

More information

TAILORx: Established and Potential Implications for Clinical Practice

TAILORx: Established and Potential Implications for Clinical Practice TAILORx: Established and Potential Implications for Clinical Practice Joseph A. Sparano, MD Study Chair, TAILORx Vice-Chair, ECOG-ACRIN Cancer Research Group Hello Healthcare Summit Berlin, Germany March

More information

The TAILORx Trial: A review of the data and implications for practice

The TAILORx Trial: A review of the data and implications for practice The TAILORx Trial: A review of the data and implications for practice Angela DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology University

More information

Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón

Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón Universidad Complutense Madrid The new technologies

More information

1 INTRODUCTION REVIEW ARTICLE

1 INTRODUCTION REVIEW ARTICLE Received: 12 December 2016 Revised: 15 December 2016 Accepted: 15 December 2016 DOI 10.1002/jso.24561 REVIEW ARTICLE Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical

More information

Contemporary Classification of Breast Cancer

Contemporary Classification of Breast Cancer Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline

More information

William J. Gradishar MD

William J. Gradishar MD Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley

More information

III Congreso Internacional de Oncologia del Interior XII Jornadas de Oncologia del Interior Cordoba Argentina. Farmacogenomica y Cancer de Mama

III Congreso Internacional de Oncologia del Interior XII Jornadas de Oncologia del Interior Cordoba Argentina. Farmacogenomica y Cancer de Mama III Congreso Internacional de Oncologia del Interior XII Jornadas de Oncologia del Interior Cordoba Argentina Farmacogenomica y Cancer de Mama Vicente Valero, M.D., F.A.C.P. Professor of Medicine Deputy

More information

What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland

What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our

More information

MEDICAL POLICY. SUBJECT: GENETIC ASSAY OF TUMOR TISSUE TO DETERMINE PROGNOSIS OF BREAST CANCER (OncotypeDX TM, MammaPrint )

MEDICAL POLICY. SUBJECT: GENETIC ASSAY OF TUMOR TISSUE TO DETERMINE PROGNOSIS OF BREAST CANCER (OncotypeDX TM, MammaPrint ) MEDICAL POLICY PAGE: 1 OF: 8 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.

More information

Principles of breast radiation therapy

Principles of breast radiation therapy ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital

More information

Emerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer

Emerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine

More information

Oncotype DX MM /01/2008. HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office

Oncotype DX MM /01/2008. HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office Oncotype DX Policy Number: Original Effective Date: MM.12.009 12/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office

More information

Postoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital

Postoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Assays of Genetic Expression to Determine Prognosis of Breast File Name: Origination: Last CAP Review: Next CAP Review: Last Review: assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer

More information

OUTCOME DISPARITIES BY AGE AND 21-GENE RECURRENCE SCORE RESULT IN HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER

OUTCOME DISPARITIES BY AGE AND 21-GENE RECURRENCE SCORE RESULT IN HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER OUTCOME DISPARITIES BY AGE AND 21-GENE RECURRENCE SCORE RESULT IN HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER Shak S, 1 Miller DP, 1 Howlader N, 2 Gliner N, 1 Howe W, 3 Schussler N, 3 Cronin K, 2 Baehner

More information

Current Status and Future Development of Tools for Prognosis and Prediction - USA

Current Status and Future Development of Tools for Prognosis and Prediction - USA Current Status and Future Development of Tools for Prognosis and Prediction - USA John H. Ward, MD Professor of Medicine University of Utah School of Medicine Huntsman Cancer Institute October18, 2009

More information

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Medical Policy Manual Genetic Testing, Policy No. 42 Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Next Review: December 2018 Last Review:

More information

Seigo Nakamura,M.D.,Ph.D.

Seigo Nakamura,M.D.,Ph.D. Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth

More information

Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives

Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast

More information

Breast cancer pathology

Breast cancer pathology Breast cancer pathology Giancarlo Pruneri, M.D. National Cancer Institute (INT) Milan University of Milan, School of Medicine Giancarlo.Pruneri@unimi.it Currently accepted prognostic/predictive parameters

More information

Medical Policy. Description. Related Policies. Policy. Effective Date January 1, 2015 Original Policy Date December 1, 2005

Medical Policy. Description. Related Policies. Policy. Effective Date January 1, 2015 Original Policy Date December 1, 2005 2.04.36 Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date January

More information

Molecular Characterization of Breast Cancer: The Clinical Significance

Molecular Characterization of Breast Cancer: The Clinical Significance Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville

More information

DIAGNOSTICS ASSESSMENT PROGRAMME

DIAGNOSTICS ASSESSMENT PROGRAMME DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10) This overview summarises the key issues

More information

THE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER CENTRE EXPERIENCE. Dr Husam Marashi 03/02/2017

THE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER CENTRE EXPERIENCE. Dr Husam Marashi 03/02/2017 THE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER CENTRE EXPERIENCE Dr Husam Marashi 03/02/2017 THE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER TODAY S TALK: CENTRE EXPERIENCE

More information

11th Annual Population Health Colloquium. Stan Skrzypczak, MS, MBA Sr. Director, Marketing Genomic Health, Inc. March 15, 2011

11th Annual Population Health Colloquium. Stan Skrzypczak, MS, MBA Sr. Director, Marketing Genomic Health, Inc. March 15, 2011 11th Annual Population Health Colloquium Stan Skrzypczak, MS, MBA Sr. Director, Marketing Genomic Health, Inc. March 15, 2011 Agenda Personalized medicine in oncology healthcare Clinical relevance of personalized

More information

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors

More information

Late Recurrence and Death in ER Positive Early Stage Breast Cancer The Next Frontier. Daniel F. Hayes, MD, FASCO, FACP Breast Oncology Program

Late Recurrence and Death in ER Positive Early Stage Breast Cancer The Next Frontier. Daniel F. Hayes, MD, FASCO, FACP Breast Oncology Program Late Recurrence and Death in ER Positive Early Stage Breast Cancer The Next Frontier Daniel F. Hayes, MD, FASCO, FACP Breast Oncology Program Conflicts of Interest Research Funding Menarini/Silicon Biosystems(Manufacturer

More information

GENOMIC TESTS FOR BREAST CANCER: FACT, MYTH, AND EVERYTHING IN BETWEEN

GENOMIC TESTS FOR BREAST CANCER: FACT, MYTH, AND EVERYTHING IN BETWEEN GENOMIC TESTS FOR BREAST CANCER: FACT, MYTH, AND EVERYTHING IN BETWEEN Adam Brufsky, MD, PhD Professor of Medicine Associate Chief, Hematology-Oncology Associate Director, Clinical Investigation University

More information

Reliable Evaluation of Prognostic & Predictive Genomic Tests

Reliable Evaluation of Prognostic & Predictive Genomic Tests Reliable Evaluation of Prognostic & Predictive Genomic Tests Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov Different Kinds of Biomarkers Prognostic

More information

Section: Genetic Testing Last Reviewed Date: March Policy No: 42 Effective Date: June 1, 2014

Section: Genetic Testing Last Reviewed Date: March Policy No: 42 Effective Date: June 1, 2014 Medical Policy Manual Topic: Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer Date of Origin: October 5, 2004 Section: Genetic Testing Last

More information

A new way of looking at breast cancer tumour biology

A new way of looking at breast cancer tumour biology A new way of looking at breast cancer tumour biology Contents Intrinsic subtypes of breast cancer 3 Gene expression assays 3 Basis of the Prosigna test 4 Information provided by Prosigna 5 The accuracy

More information

TABLE OF CONTENTS. Executive Summary The EndoPredict Test Intended Use Population Breast Cancer Clinical Dilemma. Analytical Validity

TABLE OF CONTENTS. Executive Summary The EndoPredict Test Intended Use Population Breast Cancer Clinical Dilemma. Analytical Validity Clinical Dossier TABLE OF CONTENTS Executive Summary The EndoPredict Test Intended Use Population Breast Cancer Clinical Dilemma 1 2 3 Analytical Validity 4 Clinical Validity 4 Clinical Utility 7 Medicare

More information

Comparison of prognostic signatures for ER positive breast cancer in TransATAC:

Comparison of prognostic signatures for ER positive breast cancer in TransATAC: Comparison of prognostic signatures for ER positive breast cancer in TransATAC: EndoPredict, a high performance test in node negative and node positive disease Ivana Sestak, PhD Centre for Cancer Prevention

More information

ISPOR 4 th Asia Pacific Conference IP2 Gilberto de Lima Lopes

ISPOR 4 th Asia Pacific Conference IP2 Gilberto de Lima Lopes Health Economic Considerations for Personalized Medicine in Asia: Using Genomic Profiling to Guide Treatment Decisions in Early Breast Cancer Gilberto de Lima Lopes, Jr., M.D., M.B.A Assistant Director

More information

Giuseppe Viale for the BIG 1 98 Collaborative and International Breast Cancer Study Groups

Giuseppe Viale for the BIG 1 98 Collaborative and International Breast Cancer Study Groups Central Review of ER, PgR and HER2 in BIG 1 98 Evaluating Letrozole vs. Letrozole Tamoxifen vs. Tamoxifen Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor Positive

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

Oncologist. The. A New Look at Node-Negative Breast Cancer. The Oncologist 2011;16(suppl 1):51 60

Oncologist. The. A New Look at Node-Negative Breast Cancer. The Oncologist 2011;16(suppl 1):51 60 The Oncologist A New Look at Node-Negative Breast Cancer NADIA HARBECK, a CHRISTOPH THOMSSEN b a Breast Center, University of Cologne, Cologne, Germany; b Frauenklinik der Universitaet Halle, Saale, Germany

More information

Biologic Subtypes and Prognos5c Factors. Claudine Isaacs, MD Georgetown University

Biologic Subtypes and Prognos5c Factors. Claudine Isaacs, MD Georgetown University Biologic Subtypes and Prognos5c Factors Claudine Isaacs, MD Georgetown University Prognos5c Factor Defini5on Predicts outcome in absence of systemic therapy Thus tell us when (not how) to treat a pa5ent

More information

The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer

The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia

More information

Adjuvant Systemic Therapy in Early Stage Breast Cancer

Adjuvant Systemic Therapy in Early Stage Breast Cancer Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington

More information

Choosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent

Choosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen

More information

Immunohistochemical classification of breast tumours

Immunohistochemical classification of breast tumours Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,

More information

Breast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital

Breast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant

More information

Breast Cancer Assays of Genetic Expression in Tumor Tissue

Breast Cancer Assays of Genetic Expression in Tumor Tissue Breast Cancer Assays of Genetic Expression in Tumor Tissue Policy Number: Original Effective Date: MM.12.009 12/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/16/2016

More information

Manejo do câncer de mama RH+ na adjuvância: o que há de novo?

Manejo do câncer de mama RH+ na adjuvância: o que há de novo? II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,

More information

The Latest Research: Hormonal Therapies

The Latest Research: Hormonal Therapies The Latest Research: Hormonal Therapies Sameer Gupta, M.D., M.P.H 9/29/2018 Attending Physician, Hematology/Oncology Bryn Mawr Hospital Clinical Assistant Professor, Jefferson Medical College Disclosures

More information

Why Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients

Why Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications

More information

Endocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology

Endocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer

More information

National Medical Policy

National Medical Policy National Medical Policy Subject: Policy Number: MammaPrint, Prosigna and Other Gene Expression Tests for Breast Cancer NMP520 Effective Date*: May 2013 Updated: June 2017 This National Medical Policy is

More information

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Effective Date: April 15, 2017 Related Policies: None Assays of Genetic Expression in Tumor Tissue as a Technique to Description Laboratory tests have been developed that detect

More information